Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL3291394 | 0.97 | EPHX1 (0.44) | EPHX1NPSR1CES2TRPM8MEN1 | |
| SCHEMBL30781560 | 0.88 | NPSR1 (0.45) | EPHX1NPSR1CES2MEN1KMT2A | |
| SCHEMBL1434358 | 0.87 | NPSR1 (0.44) | EPHX1NPSR1CES2MEN1KMT2A | |
| SCHEMBL2107552 | 0.83 | NPSR1 (0.44) | EPHX1NPSR1CES2MEN1KMT2A | |
| SCHEMBL1170645 | 0.82 | NPSR1 (0.41) | EPHX1NPSR1CES2HTR2AHTR2C | |
| SCHEMBL15016758 | 0.82 | ALDH1A1 (0.43) | NPSR1MEN1KMT2AALDH1A1HTR2A | |
| SCHEMBL942690 | 0.80 | GPR139 (0.42) | NPSR1MEN1KMT2AALDH1A1HTR2A | |
| SCHEMBL29600045 | 0.80 | GPR139 (0.42) | NPSR1MEN1KMT2AALDH1A1HTR2A | |
| SCHEMBL1170578 | 0.80 | GPR139 (0.42) | NPSR1MEN1KMT2AALDH1A1HTR2A | |
| SCHEMBL3746184 | 0.79 | NPSR1 (0.45) | NPSR1CES2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1889642-B1 | Cosmetic compositions combining a C-glycoside derivative and a N-acylaminoamide derivative | OREAL (FR) | 2019-05-08 | — | — | EP | claimed |
| EP-2552396-A1 | METHOD FOR CARING FOR AND/OR MAKING UP WRINKLES | L'Oréal (FR) | 2013-02-06 | — | — | EP | claimed |
| EP-1269990-B1 | Cosmetic or dermatological composition comprising acylaminoamide derivatives | OREAL (FR) | 2010-10-13 | — | — | EP | claimed |
| EP-1889642-A2 | Cosmetic compositions combining a C-glycoside derivative and a N-acylaminoamide derivative | L'OREAL (FR) | 2008-02-20 | — | — | EP | claimed |
| EP-1269988-B1 | Cosmetic or dermatological composition comprising acylaminoamide derivatives | OREAL (FR) | 2007-12-05 | — | — | EP | claimed |
| EP-1275372-B1 | Cosmetic or dermatological composition comprising a N-acylaminoamide derivative and a metalloproteinase inhibitor | OREAL (FR) | 2007-06-13 | — | — | EP | claimed |
| EP-1399113-B1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING N-ACYLAMINOAMIDE DERIVATIVES | OREAL (FR) | 2007-03-21 | — | — | EP | claimed |
| US-6962712-B2 | Cosmetic or dermatological composition comprising of a combination of an elastase inhibitor of the N-acylaminoamide family and at least one antifungal agent or at least one antibacterial agent | L'OREAL (FR) | 2005-11-08 | — | — | US | claimed |
| EP-1292608-B1 | NOVEL COMPOUNDS OF THE N-ACYLAMINO-AMIDE FAMILY, COMPOSITIONS COMPRISING SAME, AND USES | OREAL (FR) | 2004-07-21 | — | — | EP | claimed |
| EP-1399113-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING N-ACYLAMINOAMIDE DERIVATIVES | L'OREAL (FR) | 2004-03-24 | — | — | EP | claimed |
| US-20030064085-A1 | Cosmetic or dermatological composition comprising a combination of an elastase inhibitor of the N-acylaminoamide family and at least one myorelaxing agent | L'OREAL (FR) | 2003-04-03 | — | — | US | claimed |
| EP-1292608-A2 | NOVEL COMPOUNDS OF THE N-ACYLAMINO-AMIDE FAMILY, COMPOSITIONS COMPRISING SAME, AND USES | L'OREAL (FR) | 2003-03-19 | — | — | EP | claimed |
| EP-1275372-A1 | Cosmetic or dermatological composition comprising a N-acylaminoamide derivative and a metalloproteinase inhibitor | L'OREAL, S.A. (FR) | 2003-01-15 | — | — | EP | claimed |
| WO-2003000209-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING N-ACYLAMINOAMIDE DERIVATIVES | L'OREAL (FR) | 2003-01-03 | — | — | WO | claimed |
| EP-1269988-A1 | Cosmetic or dermatological composition comprising acylaminoamide derivatives | L'OREAL (FR) | 2003-01-02 | — | — | EP | claimed |
| EP-1269989-A1 | Cosmetic or dermatological composition comprising acylaminoamide derivatives | L'OREAL (FR) | 2003-01-02 | — | — | EP | claimed |
| EP-1269990-A1 | Cosmetic or dermatological composition comprising acylaminoamide derivatives | L'OREAL (FR) | 2003-01-02 | — | — | EP | claimed |
| WO-2001094381-A2 | NOVEL COMPOUNDS OF THE N-ACYLAMINO-AMIDE FAMILY, COMPOSITIONS COMPRISING SAME, AND USES | L'OREAL (FR) | 2001-12-13 | — | — | WO | claimed |
| WO-2023209021-A1 | SOLID COSMETIC CARE COMPOSITION COMPRISING AT LEAST ONE CAVITY | CAPSUM (FR) | 2023-11-02 | — | — | WO | disclosed |
| WO-2001094381-A2 | NOVEL COMPOUNDS OF THE N-ACYLAMINO-AMIDE FAMILY, COMPOSITIONS COMPRISING SAME, AND USES | L'OREAL (FR) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064085-A1 | Cosmetic or dermatological composition comprising a combination of an elastase inhibitor of the N-acylaminoamide family and at least one myorelaxing agent | ELANE, SERPINB1, MMP7 | EPHX1 689/4885NPSR1 2861/4885CES2 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.